NEW YORK (GenomeWeb) – Belgian cancer theranostics firm OncoDNA today announced an exclusive distribution deal granting Greek anatomic pathology laboratory Istomedica the exclusive rights to OncoDNA's products in Greece.
OncoDNA will be Istomedica's preferred supplier of clinical grade molecular theranostics using OncoDeep Dx, which links specific genes to targeted cancer treatments, and clinical cancer panels, in combination with Package Plus, a set of cancer tests based on immunohistochemical, fluorescent in situ hybridization, methylation, and other technologies.
As a result of the deal, clinicians in Greece will be able to access next-generation sequencing-based technology providing them with clinically relevant interpretations of tumors with the OncoShare web platform, OncoDNA said.
"With this distribution agreement, OncoDNA is continuing to fulfill its ambitions, using innovations based on molecular characterization of tumor to help medical doctors make the right treatment choice and better monitor tumor development in the patient," OncoDNA Founder and CEO Jean-Pol Detiffe said in a statement.
OncoDNA, an affiliated company of Belgium's Institute of Pathology and Genetics, provides NGS and IHC testing to help oncologists make drug treatment choices. Athens, Greece-based Istomedica provides full histological, IHC, and molecular testing.